Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

1.29
-0.3349-20.67%
Volume:3.63M
Turnover:5.23M
Market Cap:29.12M
PE:-0.10
High:1.61
Open:1.50
Low:1.27
Close:1.62
52wk High:10.99
52wk Low:1.27
Shares:22.66M
Float Shares:15.77M
Volume Ratio:21.44
T/O Rate:23.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0816
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-47.61%
PB:-0.09
PE(LYR):-0.07

Loading ...

Karyopharm’s selinexor combination shows efficacy in myelofibrosis

TIPRANKS
·
Jun 02

Karyopharm's Phase 3 Sentry Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at Eha 2026

THOMSON REUTERS
·
Jun 02

Karyopharm says Phase 3 SENTRY trial shows selinexor-ruxolitinib combo lifts SVR35 in myelofibrosis

Reuters
·
Jun 02

Karyopharm grants 1,200 RSUs to newly hired employee under inducement plan

Reuters
·
Jun 02

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 02

Karyopharm to discuss Phase 3 SENTRY trial results for selinexor plus ruxolitinib in myelofibrosis at June 2 call

Reuters
·
Jun 01

Karyopharm Therapeutics shareholders approve 3 million-share increase to 2022 equity plan at annual meeting

Reuters
·
May 29

Karyopharm management participates in Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 28

Karyopharm (KPTI) Leans on SENTRY in Pivotal Call

TIPRANKS
·
May 20

Karyopharm publishes corporate presentation highlighting selinexor Phase 3 trial readouts in 2026

Reuters
·
May 19

Karyopharm Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Karyopharm Q1 net loss narrows

Reuters
·
May 14

Karyopharm Therapeutics Q1 EPS $(1.24) Beats $(1.40) Estimate, Sales $35.066M Beat $31.399M Estimate

Benzinga Earnings
·
May 14

Karyopharm Therapeutics Outlook FY Revenue USD 130-150 Million

THOMSON REUTERS
·
May 14

Karyopharm Therapeutics Q1 Net Income USD -22.392 Million

THOMSON REUTERS
·
May 14

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment

THOMSON REUTERS
·
May 14

Karyopharm Therapeutics Inc expected to post a loss of $1.43 a share - Earnings Preview

Reuters
·
May 12

Karyopharm management joins H.C. Wainwright BioConnect investor conference fireside chat

Reuters
·
May 12

Karyopharm to report Q1 2026 results, host conference call

Reuters
·
May 07

Karyopharm price target raised to $13 from $8 at H.C. Wainwright

TIPRANKS
·
May 07